PL3331894T3 - Pochodne mononukleotydu nikotynamidowego i ich zastosowania - Google Patents
Pochodne mononukleotydu nikotynamidowego i ich zastosowaniaInfo
- Publication number
- PL3331894T3 PL3331894T3 PL16833957T PL16833957T PL3331894T3 PL 3331894 T3 PL3331894 T3 PL 3331894T3 PL 16833957 T PL16833957 T PL 16833957T PL 16833957 T PL16833957 T PL 16833957T PL 3331894 T3 PL3331894 T3 PL 3331894T3
- Authority
- PL
- Poland
- Prior art keywords
- nicotinamide mononucleotide
- mononucleotide derivatives
- derivatives
- nicotinamide
- mononucleotide
- Prior art date
Links
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical class NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
- C07H11/04—Phosphates; Phosphites; Polyphosphates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562201447P | 2015-08-05 | 2015-08-05 | |
| EP16833957.0A EP3331894B1 (en) | 2015-08-05 | 2016-08-05 | Nicotinamide mononucleotide derivatives and their uses |
| PCT/US2016/045855 WO2017024255A1 (en) | 2015-08-05 | 2016-08-05 | Nicotinamide mononucleotide derivatives and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3331894T3 true PL3331894T3 (pl) | 2021-08-23 |
Family
ID=57944181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16833957T PL3331894T3 (pl) | 2015-08-05 | 2016-08-05 | Pochodne mononukleotydu nikotynamidowego i ich zastosowania |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US9855289B2 (pl) |
| EP (1) | EP3331894B1 (pl) |
| JP (1) | JP6949002B6 (pl) |
| KR (1) | KR102354784B1 (pl) |
| CN (1) | CN108137639B (pl) |
| AU (1) | AU2016302005B2 (pl) |
| BR (1) | BR112018002168B1 (pl) |
| CA (1) | CA2994553C (pl) |
| DK (1) | DK3331894T3 (pl) |
| EA (1) | EA035664B1 (pl) |
| ES (1) | ES2862170T3 (pl) |
| IL (1) | IL257327B (pl) |
| MX (1) | MX2018001363A (pl) |
| PL (1) | PL3331894T3 (pl) |
| PT (1) | PT3331894T (pl) |
| WO (1) | WO2017024255A1 (pl) |
| ZA (1) | ZA201801196B (pl) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3331894T3 (da) | 2015-08-05 | 2021-03-22 | Metro Int Biotech Llc | Nicotinamidmononukleotidderivater og anvendelser deraf |
| GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
| WO2017079195A1 (en) | 2015-11-02 | 2017-05-11 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
| ES2948968T3 (es) | 2016-04-20 | 2023-09-22 | Chromadex Inc | Uso del ribósido de ácido nicotínico o derivados del ribósido de nicotinamida, y derivados reducidos de los mismos, como precursores que aumentan el NAD++ |
| US20200009170A1 (en) * | 2016-09-13 | 2020-01-09 | Megumi Tanaka | Sleep display agent property and method for improving sleep disorders |
| US11286274B2 (en) | 2017-06-19 | 2022-03-29 | Mitopower Llc | Nicotinamide riboside derivatives and their uses |
| US11180521B2 (en) | 2018-01-30 | 2021-11-23 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
| WO2019182044A1 (ja) * | 2018-03-22 | 2019-09-26 | オリエンタル酵母工業株式会社 | 多分化能性幹細胞分化促進剤 |
| US10654883B2 (en) | 2018-05-15 | 2020-05-19 | Jumpstart Fertility Pty Ltd | Inorganic salts of nicotinic acid mononucleotide as anti-aging agents |
| WO2020131578A2 (en) * | 2018-12-17 | 2020-06-25 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| US11491175B2 (en) | 2019-02-25 | 2022-11-08 | Celagenex Research (India) Pvt. Ltd. | Synergistic bioactive compositions for enhancing cellular energy |
| US10618927B1 (en) | 2019-03-22 | 2020-04-14 | Metro International Biotech, Llc | Compositions and methods for modulation of nicotinamide adenine dinucleotide |
| US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
| JP2022541058A (ja) | 2019-07-19 | 2022-09-21 | バイオシント アクチェンゲゼルシャフト | ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用 |
| RS65256B1 (sr) | 2019-09-09 | 2024-03-29 | Nuvamid Sa | Upotreba nmn za prevenciju i/ili lečenje bola i odgovarajuće kompozicije |
| FR3100449B1 (fr) | 2019-09-09 | 2022-08-26 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement de la douleur et compositions correspondantes |
| FR3102058A1 (fr) * | 2019-10-18 | 2021-04-23 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes |
| CN112823778B (zh) * | 2019-11-21 | 2024-06-14 | 百瑞全球有限公司 | 毛发护理组合物及其制备方法 |
| FR3103702B1 (fr) | 2019-11-28 | 2022-02-11 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes |
| FR3106056B1 (fr) | 2020-01-13 | 2021-12-17 | Nuvamid | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur articulaire induite par l’activité physique et compositions correspondantes |
| FR3107897B1 (fr) * | 2020-03-06 | 2023-05-26 | Nuvamid Sa | Dérivés de nicotinamide mononucléotides |
| FR3108031B1 (fr) | 2020-03-12 | 2024-02-16 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes |
| FR3108032B1 (fr) | 2020-03-12 | 2024-02-16 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes |
| CN115315507A (zh) * | 2020-03-30 | 2022-11-08 | 东方酵母工业株式会社 | 干细胞的染色体稳定剂 |
| EP3901160A1 (en) * | 2020-04-25 | 2021-10-27 | Nuvamid SA | Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus |
| JP2023522383A (ja) * | 2020-04-24 | 2023-05-30 | ヌヴァミド エスアー | ニコチンアミドモノヌクレオチド及びニコチンアミドリボシド誘導体、並びに特にインフルエンザウィルス又はコロナウィルスによって引き起こされるウィルス感染症及び呼吸器合併症の治療におけるそれらの使用 |
| JP2023524389A (ja) * | 2020-05-05 | 2023-06-12 | コナゲン インコーポレイテッド | 微生物プロセスを介したｎｍｎおよびその誘導体の生成 |
| FR3110410A1 (fr) | 2020-05-20 | 2021-11-26 | Nuvamid Sa | Compositions cosmétiques anti-âge comprenant de la NMN |
| US20230210746A1 (en) | 2020-05-20 | 2023-07-06 | Nuvamid Sa | Anti-aging cosmetic compositions comprising nmn |
| FR3110836B1 (fr) | 2020-05-29 | 2023-06-16 | Nuvamid | Utilisation de NMN pour réduire l’immunodépression et l’immunosénescence |
| CN111548383B (zh) * | 2020-06-11 | 2023-04-18 | 湖南和泰康瑞生物技术有限公司 | 一种β-烟酰胺单核苷酸的工艺制备方法 |
| CN111956670A (zh) * | 2020-08-31 | 2020-11-20 | 杭州伊瑟奇生物科技有限公司 | 一种间充质干细胞及其活性因子复合物冻干品的制备方法 |
| WO2022047779A1 (zh) * | 2020-09-07 | 2022-03-10 | 音芙医药科技(上海)有限公司 | 烟酰胺单核苷酸在制备提高损伤皮肤肌膜中Na+-K+-ATP酶水平试剂中的应用 |
| CN112094362B (zh) * | 2020-09-29 | 2022-04-12 | 四川大学华西医院 | 烟酰胺核糖或单核苷酸类似物-大分子载体轭合物及制法和应用 |
| WO2022094916A1 (zh) * | 2020-11-06 | 2022-05-12 | 中国科学院深圳先进技术研究院 | 一种提高烟酰胺磷酸核糖转移酶活性的方法及其组合物 |
| CN112500445B (zh) * | 2020-12-04 | 2022-11-29 | 黄冈鲁班药业股份有限公司 | β-烟酰胺核糖的制备方法 |
| IT202100005054A1 (it) * | 2021-03-04 | 2022-09-04 | Azienda Ospedaliero Univ Di Parma | Composto farmaceutico per l’uso in un trattamento terapeutico dell’infezione cronica da hbv e metodo per l’identificazione di linfociti esauriti |
| KR102633321B1 (ko) * | 2021-05-11 | 2024-02-05 | 연세대학교 산학협력단 | 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물 |
| WO2022251491A1 (en) | 2021-05-27 | 2022-12-01 | Metro International Biotech, Llc | Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use |
| CN115304655A (zh) * | 2021-11-23 | 2022-11-08 | 中立安(北京)医药科技有限公司 | 烟酰胺单核苷类衍生物及其制备方法和应用 |
| CN118541157A (zh) | 2021-12-22 | 2024-08-23 | 麦德龙国际生物科技有限责任公司 | 用于治疗炎症的组合物 |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
| CN114540283B (zh) * | 2022-01-27 | 2023-10-20 | 中国农业科学院北京畜牧兽医研究所 | 用于牛体外胚胎生产的高效玻璃化冷冻方法 |
| US12065404B2 (en) | 2022-03-18 | 2024-08-20 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| CN115611960A (zh) * | 2022-11-18 | 2023-01-17 | 翔鹏(北京)生物科技有限公司 | 一种人体辅酶i前体的制备方法 |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3201389A (en) | 1962-09-24 | 1965-08-17 | Kyowa Hakko Kogyo Kk | Method for preparing ribonucleoside-5'-phosphates or their salts from ribonucleosides |
| US3451997A (en) | 1965-11-30 | 1969-06-24 | Kyowa Hakko Kogyo Kk | Monothio-phosphate ester catalysis for preparation of ribonucleoside derivatives |
| US4411995A (en) | 1981-09-28 | 1983-10-25 | Massachusetts Institute Of Technology | Synthesis of nicotinamide cofactors |
| US5318508A (en) | 1991-03-15 | 1994-06-07 | Elvira Osthold | Nail corrective brace |
| US7560442B2 (en) | 2001-04-30 | 2009-07-14 | Trommsdorff Gmbh & Co. Kg Arzneimittel | Pharmaceutically active uridine esters |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US20040224039A1 (en) | 2003-02-12 | 2004-11-11 | Donald Brucker | Compositions and methods for the treatment of diseases and disorder associated with oxidative damage |
| WO2006072809A2 (en) | 2003-10-31 | 2006-07-13 | Robarts Research Institute | Formulations that optimize intracellular concentration of nicotinamide adenine (nad+) and methods of use to protect cells and treat diseases and conditions |
| US7776326B2 (en) | 2004-06-04 | 2010-08-17 | Washington University | Methods and compositions for treating neuropathies |
| EP1877054A2 (en) | 2005-03-30 | 2008-01-16 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| US20090118223A1 (en) | 2005-08-12 | 2009-05-07 | Erion Mark D | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives |
| EP3730507A1 (en) | 2005-11-18 | 2020-10-28 | Cornell Research Foundation, Inc. | Nicotinoyl riboside and nicotinamide riboside compositions for use in reducing toxicity induced by hmg-coa reductase inhibitors |
| US20080318892A1 (en) | 2006-04-28 | 2008-12-25 | John Geoffrey Pickering | Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad |
| TW200936146A (en) | 2007-11-29 | 2009-09-01 | Metabasis Therapeutics Inc | Antiviral nucleoside compounds |
| CN101497638B (zh) * | 2008-01-30 | 2012-09-26 | 中国科学院大连化学物理研究所 | 一种nad+类似物及其合成和应用 |
| BRPI0910455B8 (pt) | 2008-04-23 | 2021-05-25 | Gilead Sciences Inc | análogos de carba-nucleosídeo 1-substituído para tratamento antiviral e composição farmacêutica que os compreende |
| CN101601679B (zh) | 2009-03-17 | 2011-08-10 | 中国人民解放军第二军医大学 | 一种烟酰胺单核苷酸的应用 |
| US20100297079A1 (en) * | 2009-05-20 | 2010-11-25 | Chimerix, Inc. | Compounds, compositions and methods for treating viral infection |
| TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| WO2012004917A1 (ja) | 2010-07-06 | 2012-01-12 | Kaminishi Hidenori | 神経突起伸長剤 |
| KR20130114653A (ko) | 2010-09-03 | 2013-10-17 | 포르마 티엠, 엘엘씨. | 암과 같은 질환의 치료를 위한 ｎａｍｐｔ 억제제로서의 4-｛［（피리딘-3-일-메틸）아미노카르보닐］아미노｝벤젠-술폰 유도체 |
| PE20140011A1 (es) | 2010-09-03 | 2014-01-31 | Forma Tm Llc | Compuestos y composiciones novedosos para la inhibicion de nampt |
| EP2611778B1 (en) | 2010-09-03 | 2015-08-05 | Forma TM, LLC. | Guanidine compounds and compositions for the inhibition of nampt |
| WO2012094343A1 (en) * | 2011-01-05 | 2012-07-12 | Trilink Biotechnologies | Chemically substituted thermosensitive probes and cofactors for hot start ligation |
| WO2012114204A2 (en) | 2011-02-15 | 2012-08-30 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Methods of treating mitochondrial dysfunction |
| US20120107888A1 (en) | 2011-02-17 | 2012-05-03 | Qteros, Inc. | Modulation of fermentation products through vitamin supplementation |
| JP5978293B2 (ja) | 2011-05-04 | 2016-08-24 | フォーマ ティーエム， エルエルシー． | Ｎａｍｐｔを阻害するための新規な化合物および組成物 |
| US20120328526A1 (en) | 2011-06-27 | 2012-12-27 | University Of Maryland, Baltimore | Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof |
| US20130143835A1 (en) | 2011-12-05 | 2013-06-06 | Medivir Ab | HCV Polymerase Inhibitors |
| WO2013127268A1 (en) | 2012-03-02 | 2013-09-06 | Genentech,Inc. | Amido-benzyl sulfone and sulfonamide derivatives |
| SG11201405054PA (en) | 2012-03-02 | 2014-09-26 | Genentech Inc | Amido-benzyl sulfone and sulfoxide derivatives |
| WO2013130943A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Alkyl-and di-substituted amido-benzyl sulfonamide derivatives |
| WO2013127267A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives |
| PT2820008T (pt) | 2012-03-02 | 2017-05-05 | Genentech Inc | Amidas amido-espirocíclicas e derivados de sulfonamidas |
| MX355708B (es) | 2012-05-22 | 2018-04-27 | Idenix Pharmaceuticals Llc | Compuestos de d-aminoacidos para enfermedades del higado. |
| EP2872128B1 (en) | 2012-07-16 | 2020-02-19 | Cornell University | Nicotinamide riboside to treat hearing loss |
| WO2014059034A2 (en) | 2012-10-09 | 2014-04-17 | President And Fellows Of Harvard College | Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation |
| CN102876759A (zh) | 2012-10-29 | 2013-01-16 | 尚科生物医药（上海）有限公司 | 尼克酰胺腺嘌呤二核苷酸的制备方法 |
| WO2014074715A1 (en) | 2012-11-07 | 2014-05-15 | Genentech, Inc. | Cyclopropyl amide derivatives |
| WO2014111906A1 (en) | 2013-01-21 | 2014-07-24 | Ecole Polytechnique Federale De Lausanne (Epfl) | Bioluminescence imaging of small biomolecules |
| US20140271355A1 (en) | 2013-03-15 | 2014-09-18 | Sabre Intellectual Property Holdings Llc | Apparatus and process for focused gas phase application of biocide |
| WO2014146044A1 (en) | 2013-03-15 | 2014-09-18 | Washington University | Administration of nicotinamide mononucleotide in the treatment of disease |
| GB201313465D0 (en) | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
| US20160287621A1 (en) | 2013-11-06 | 2016-10-06 | President And Fellows Of Harvard College | Biological production of nad precursors and analogs |
| US10398701B2 (en) | 2013-11-12 | 2019-09-03 | Ortho-Nutra, Llc | Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine |
| CN105992521A (zh) | 2013-11-12 | 2016-10-05 | 奥索努特拉有限责任公司 | 基于特咖宁的补充剂及其使用方法 |
| CN104367587B (zh) | 2013-12-06 | 2018-06-29 | 中国人民解放军第二军医大学 | 烟酰胺单核苷酸在制备促脑缺血后神经再生药物中的应用 |
| US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| US20150258052A1 (en) | 2014-03-13 | 2015-09-17 | Salk Institute For Biological Studies | Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue |
| AU2015229055B2 (en) | 2014-03-13 | 2019-09-12 | Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| AU2015270130A1 (en) | 2014-06-02 | 2016-12-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Preparation and use of crystalline beta-D-nicotinamide riboside |
| MX2016016071A (es) | 2014-06-06 | 2017-07-11 | Glaxosmithkline Intellectual Property (No 2) Ltd | Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos. |
| WO2016014927A2 (en) | 2014-07-24 | 2016-01-28 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| CN107428791B (zh) | 2015-03-09 | 2024-05-28 | 格雷斯公司 | 烟酰胺核苷的结晶形式 |
| CN104817604B (zh) | 2015-03-16 | 2017-08-04 | 邦泰生物工程(深圳)有限公司 | 一种β‑烟酰胺单核苷酸的纯化方法 |
| WO2016149672A1 (en) | 2015-03-18 | 2016-09-22 | The Regents Of The University Of California | Methods of preventing and reversing stem cell aging |
| US20160355539A1 (en) | 2015-06-04 | 2016-12-08 | Chromadex, Inc. | Selective solvent free phosphorylation |
| DK3331894T3 (da) | 2015-08-05 | 2021-03-22 | Metro Int Biotech Llc | Nicotinamidmononukleotidderivater og anvendelser deraf |
| TW201713774A (zh) | 2015-08-06 | 2017-04-16 | Kohjin Life Sciences Co Ltd | 含有β-菸鹼醯胺單核苷酸的酵母萃取物及其製造方法 |
| GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
| SG11201802933YA (en) | 2015-10-07 | 2018-05-30 | Joel Huizenga | Resetting biological pathways for defending against and repairing deterioration from human aging |
| WO2017079195A1 (en) * | 2015-11-02 | 2017-05-11 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
| US10654882B2 (en) | 2015-12-21 | 2020-05-19 | Showa Denko K.K. | Nicotinamide mononucleotide derivative and salt thereof, method for producing same, topical skin preparation, cosmetic and food additive |
| EP3187180A1 (en) | 2015-12-28 | 2017-07-05 | Ludwig-Maximilians-Universität München | Adenosylhomocysteinase binding substances for medical use |
| US11248018B2 (en) | 2016-02-23 | 2022-02-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Process for preparation of nicotinamide riboside (NR) and cosmetic composition comprising (NR and a phosphate-binding agent |
| AU2017232930B2 (en) | 2016-03-16 | 2021-03-25 | ChromaDex Inc. | B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof |
| ES2948968T3 (es) | 2016-04-20 | 2023-09-22 | Chromadex Inc | Uso del ribósido de ácido nicotínico o derivados del ribósido de nicotinamida, y derivados reducidos de los mismos, como precursores que aumentan el NAD++ |
| WO2017218580A1 (en) | 2016-06-14 | 2017-12-21 | Rejuvenation Therapeutics Corporation | Synthetic methods for the preparation of nicotinamide riboside and related compounds |
| CN108026535B (zh) | 2016-07-30 | 2021-04-27 | 邦泰生物工程(深圳)有限公司 | 一种制备烟酰胺单核苷酸的方法 |
| CN107889504B (zh) | 2016-07-30 | 2021-07-27 | 邦泰生物工程(深圳)有限公司 | 一种制备烟酰胺单核苷酸的方法 |
| WO2017185549A1 (zh) | 2016-07-30 | 2017-11-02 | 邦泰生物工程(深圳)有限公司 | 一种制备烟酰胺单核苷酸的方法2 |
| WO2018023208A1 (zh) | 2016-07-30 | 2018-02-08 | 邦泰生物工程(深圳)有限公司 | 一种制备烟酰胺单核苷酸的方法 |
| WO2018023210A1 (zh) | 2016-07-30 | 2018-02-08 | 邦泰生物工程(深圳)有限公司 | 一种制备烟酰胺单核苷酸的方法 |
| WO2018023205A1 (zh) | 2016-07-30 | 2018-02-08 | 邦泰生物工程(深圳)有限公司 | 一种烟酰胺单核苷酸的纯化方法 |
| WO2018047715A1 (ja) | 2016-09-06 | 2018-03-15 | 協和発酵バイオ株式会社 | β－ニコチンアミドモノヌクレオチドの結晶及びその製造方法 |
| US11502831B2 (en) | 2016-09-09 | 2022-11-15 | Nec Corporation | Transmitting device, receiving device, quantum key distribution method, and quantum key distribution program for quantum key distribution system |
| US20200009170A1 (en) | 2016-09-13 | 2020-01-09 | Megumi Tanaka | Sleep display agent property and method for improving sleep disorders |
| US10898738B2 (en) | 2016-09-13 | 2021-01-26 | Megumi Tanaka | Visual function printing agent, and method for improving visual functions |
| US9975915B1 (en) | 2016-11-11 | 2018-05-22 | The Queen's University Of Belfast | Crystalline forms of nicotinoyl ribosides, modified derivatives thereof, and phosphorylated analogs thereof, and methods of preparation thereof |
| CN106755209B (zh) | 2016-12-29 | 2021-07-23 | 苏州汉酶生物技术有限公司 | 一种酶法制备β-烟酰胺单核苷酸的方法 |
| US20200121704A1 (en) | 2017-01-13 | 2020-04-23 | The Regents Of The University Of Colorado, A Body Corporate | Methods for treating hypertension and arterial stiffness |
| EP3578639A4 (en) | 2017-01-31 | 2020-07-08 | Oriental Yeast Co., Ltd. | MEANS TO ACCELERATE THE GROWTH OF STEM CELLS WITH DIFFERENTIATION POTENTIAL |
| JP6920071B2 (ja) | 2017-02-16 | 2021-08-18 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | アディポネクチン分泌向上剤 |
| PL3606929T3 (pl) | 2017-04-05 | 2021-12-27 | Cornell University | Nukleotydy estru beta-nikotynianowego i sposoby ich wytwarzania |
| EP3661601A4 (en) | 2017-07-31 | 2020-10-07 | Newsouth Innovations Pty Limited | PROCESS FOR INCREASING FERTILITY |
| US11180521B2 (en) | 2018-01-30 | 2021-11-23 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
| EP3893873A4 (en) | 2018-12-10 | 2023-01-11 | Chromadex, Inc. | CRYSTALLINE FORMS OF NICOTINOYL RIBOSIDES AND THEIR DERIVATIVES AND PROCESSES FOR THEIR PRODUCTION |
| JP2022523864A (ja) | 2019-03-22 | 2022-04-26 | メトロ インターナショナル バイオテック，エルエルシー | ニコチンアミドリボシドのリン誘導体を含む組成物及びニコチンアミドアデニンジヌクレオチドのモジュレーションのための方法 |
| US10618927B1 (en) | 2019-03-22 | 2020-04-14 | Metro International Biotech, Llc | Compositions and methods for modulation of nicotinamide adenine dinucleotide |
| US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
| WO2022251491A1 (en) | 2021-05-27 | 2022-12-01 | Metro International Biotech, Llc | Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use |
-
2016
- 2016-08-05 DK DK16833957.0T patent/DK3331894T3/da active
- 2016-08-05 US US15/512,388 patent/US9855289B2/en active Active
- 2016-08-05 BR BR112018002168-7A patent/BR112018002168B1/pt active IP Right Grant
- 2016-08-05 CA CA2994553A patent/CA2994553C/en active Active
- 2016-08-05 MX MX2018001363A patent/MX2018001363A/es unknown
- 2016-08-05 AU AU2016302005A patent/AU2016302005B2/en active Active
- 2016-08-05 ES ES16833957T patent/ES2862170T3/es active Active
- 2016-08-05 KR KR1020187006160A patent/KR102354784B1/ko active IP Right Grant
- 2016-08-05 CN CN201680059161.5A patent/CN108137639B/zh active Active
- 2016-08-05 EA EA201890435A patent/EA035664B1/ru unknown
- 2016-08-05 PL PL16833957T patent/PL3331894T3/pl unknown
- 2016-08-05 WO PCT/US2016/045855 patent/WO2017024255A1/en active Application Filing
- 2016-08-05 JP JP2018505479A patent/JP6949002B6/ja active Active
- 2016-08-05 EP EP16833957.0A patent/EP3331894B1/en active Active
- 2016-08-05 PT PT168339570T patent/PT3331894T/pt unknown
-
2017
- 2017-03-20 US US15/463,683 patent/US9919003B2/en active Active
-
2018
- 2018-01-23 US US15/877,597 patent/US10548913B2/en active Active
- 2018-02-04 IL IL257327A patent/IL257327B/en unknown
- 2018-02-21 ZA ZA2018/01196A patent/ZA201801196B/en unknown
-
2019
- 2019-12-13 US US16/713,711 patent/US11464796B2/en active Active
-
2022
- 2022-07-26 US US17/873,577 patent/US11878027B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201801196B (en) | Nicotinamide mononucleotide derivatives and their uses | |
| SG11201912267SA (en) | Nicotinamide riboside derivatives and their uses | |
| IL253656A0 (en) | Mono- and polyazanephthalene modified histories and their use | |
| HUE061440T2 (hu) | Helyettesített policiklusos piridon-származékok és azok elõgyógyszere | |
| PL3181560T3 (pl) | Pochodna pirydynoamidopirymidyny, sposób jej otrzymywania i zastosowanie | |
| EP3268362A4 (en) | Substituted pyridines and uses thereof | |
| GB201400787D0 (en) | Heteroaryl alkyne derivatives and uses thereof | |
| HK1246156B (zh) | Fgf21衍生物及其用途 | |
| RS64012B1 (sr) | Derivati supstituisanog policikličnog piridona i njihov prolek | |
| HK1251226A1 (zh) | 吡啶和嘧啶衍生物 | |
| ZA201701066B (en) | Pyridine derivatives and anti-mycobacterial use thereof | |
| SG10201913045PA (en) | A solid state form of pladienolide pyridine compounds and methods of use | |
| HUE057328T2 (hu) | Aminopiridin származékok és szelektív ALK-2 gátlóként való alkalmazásuk | |
| HK1247192A1 (zh) | 吡啶或嘧啶衍生物 | |
| HK1253530A1 (zh) | 二氨基吡啶衍生物 | |
| PL3263133T3 (pl) | Związek pirydynonu i jego zastosowanie | |
| IL258690A (en) | Pyridone derivatives and their use as kinase inhibitors | |
| PT3228616T (pt) | Derivados de piridina | |
| HUE050178T2 (hu) | Piridinon vegyület és alkalmazása |